Rosuvastatin: Indications, Dosing, and Side Effects
Rosuvastatin is a highly effective HMG-CoA reductase inhibitor indicated for reducing cardiovascular risk and managing dyslipidemia, with a dosing range of 5-40 mg daily depending on patient characteristics and treatment goals. 1
Primary Indications
Rosuvastatin is FDA-approved for:
- Cardiovascular risk reduction in adults without established coronary heart disease who have elevated CV risk (based on age, hsCRP ≥2 mg/L, and additional risk factors)
- Primary hyperlipidemia as adjunct to diet to reduce LDL-C
- Heterozygous familial hypercholesterolemia (HeFH) in adults and pediatric patients ≥8 years
- Homozygous familial hypercholesterolemia (HoFH) in patients ≥7 years
- Primary dysbetalipoproteinemia and hypertriglyceridemia in adults 1
Recommended Dosing
Adults
Standard dosing range: 5-40 mg once daily, taken with or without food at any time of day 1, 2
- Moderate-intensity therapy: Rosuvastatin 5-10 mg (achieves 30-49% LDL-C reduction) 2, 3
- High-intensity therapy: Rosuvastatin 20-40 mg (achieves ≥50% LDL-C reduction) 2, 3
Special Populations Requiring Dose Adjustments
Asian patients: Start at 5 mg daily due to higher plasma levels; carefully consider risks/benefits if doses >20 mg needed 4, 1
Severe renal impairment (CrCl <30 mL/min, not on hemodialysis): Start at 5 mg daily; do not exceed 10 mg daily 5, 1
Chronic kidney disease (eGFR <60 mL/min): KDIGO guidelines recommend avoiding high-intensity statins and reducing doses, though FDA labeling for rosuvastatin doesn't require adjustment until CrCl <30 mL/min 6, 5
Pediatric Dosing
- HeFH (ages 8-<10 years): 5-10 mg daily
- HeFH (ages ≥10 years): 5-20 mg daily
- HoFH (ages ≥7 years): 20 mg daily 1
Clinical Efficacy
Rosuvastatin demonstrates superior LDL-C lowering compared to other statins at equivalent doses. At 5-40 mg daily, rosuvastatin produces 39-63% mean LDL-C reductions 7, 8. Notably, rosuvastatin 5 mg reduces LDL-C by approximately 42%, significantly more than atorvastatin 10 mg (36%), simvastatin 20 mg (36%), or pravastatin 20 mg (27%) 9.
The drug also favorably impacts other lipid parameters, raising HDL-C by approximately 10% and reducing triglycerides 10.
Side Effects and Safety Considerations
Common Side Effects (≥2% incidence)
- Headache
- Nausea
- Myalgia
- Asthenia (weakness)
- Constipation 1
Serious Adverse Effects
Myopathy and rhabdomyolysis: The most clinically significant concern. Risk factors include:
- Age ≥65 years
- Asian descent
- Uncontrolled hypothyroidism
- Renal impairment
- Higher rosuvastatin doses
- Concomitant use of certain medications (gemfibrozil, cyclosporine, protease inhibitors) 1
Instruct patients to immediately report unexplained muscle pain, tenderness, or weakness, especially with fever or malaise. Discontinue rosuvastatin if markedly elevated CK levels occur or myopathy is suspected 1.
Hepatic dysfunction: Increases in serum transaminases can occur. Consider baseline liver enzyme testing and monitor as clinically indicated. Discontinue promptly if serious hepatic injury with symptoms, hyperbilirubinemia, or jaundice develops 1.
Immune-mediated necrotizing myopathy (IMNM): Rare autoimmune myopathy reported with statin use; discontinue if suspected 1
Proteinuria and hematuria: May occur with rosuvastatin; consider dose reduction if develops 1
Increased blood glucose: Rosuvastatin may elevate blood sugar levels 1
Drug Interactions
Critical interactions requiring dose adjustments or avoidance:
- Cyclosporine: Contraindicated or requires significant dose reduction 11
- Gemfibrozil: Increases myopathy risk substantially more than fenofibrate; use fenofibrate if fibrate needed 11
- Protease inhibitors (lopinavir/ritonavir, atazanavir, etc.): Significantly increase rosuvastatin levels 1
- Warfarin: Monitor INR closely upon initiation, dose changes, or discontinuation 1
- Aluminum/magnesium antacids: Administer rosuvastatin at least 2 hours before antacid 1
Rosuvastatin undergoes minimal CYP450 metabolism (only 10% via CYP2C9), resulting in fewer drug interactions compared to statins extensively metabolized by CYP3A4 (simvastatin, lovastatin, atorvastatin) 11, 8.
Monitoring Recommendations
- Assess LDL-C as early as 4 weeks after initiating therapy and adjust dosage as needed 1
- Monitor liver enzymes before therapy and as clinically indicated
- Evaluate for muscle symptoms at each visit
- In patients with renal impairment, monitor for proteinuria and adjust dose accordingly
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to rosuvastatin or any excipients
- Pregnancy and lactation 1